Trial death prompts FDA to stop study of Advaxis candidate

14 March 2018

Shares in Advaxis (Nasdaq: ADXS) slumped over 10% yesterday as the I-O specialist revealed it had been forced to stop its Phase I/II study of axalimogene filolisbac with Imfinzi (durvalumab), following a trial death.

The news was buried in a generally positive annual financial statement which outlined the firm’s current cash position, which was said to be “sufficient to fund its business plan into the second calendar quarter of 2019.”

Advaxis’ combination study, which is exploring treatment for certain patients with cervical cancer and HPV-associated head and neck cancer, will remain paused while the FDA carries out its investigation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK